FDA Inspection
Immunex Rhode Island CorporationImmunex Rhode Island Corporation – FDA Inspection, Feb 3, 2017
Record Details
This FDA Inspection record concerns Immunex Rhode Island Corporation, with an inspection on February 3, 2017, issued by the New England District Office, covering human drugs.
- People
- Michael Shanks (Issuing Officer)
- Nealie C. Newberger
View Company Profile
ID · f2c9a894-b6fb-447d-9ee9-cb4048a79ef3
Inspection Facts
- Inspection number
- 1000373
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Immunex Rhode Island Corporation
8| Date | Classification | Office | Project area |
|---|---|---|---|
| June 3, 2026 | Not classified | New England District Office | |
| October 27, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 19, 2019 | Not classified | New England District Office | |
| November 2, 2018 | Not classified | New England District Office | |
| July 17, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Immunex Rhode Island Corporation
- FDA Inspection 1324094 - 2026-06-03
- FDA Inspection 1191233 - 2022-10-27
- FDA Inspection 1092675 - 2019-04-19
- FDA Inspection 1071184 - 2018-11-02
- FDA Inspection 1028526 - 2017-07-17
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.